%PDF-1.4
%
41 0 obj
<>
endobj
38 0 obj
<>
endobj
89 1 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-01-14T18:06:57Z
2024-03-29T03:09:23-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T03:09:23-07:00
application/pdf
Heather
2002-29.dec02
uuid:dc0ebe78-1dd1-11b2-0a00-bc0827fd5800
uuid:dc0ebe7b-1dd1-11b2-0a00-6a0000000000
endstream
endobj
27 0 obj
<>
endobj
28 0 obj
<>
endobj
42 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 15 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 17 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 19 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
124 0 obj
[128 0 R]
endobj
125 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.1113 Tw 10 0 0 10 54 713.1616 Tm
[(international collaborative ef)17.7 (fort is currently under way to)]TJ
0.0294 Tw 0 -1.2 TD
(determine with precision both the risk of cancer occurrence)Tj
0.1008 Tw T*
(in SLE and the influence of drugs and other exposures on)Tj
0.02499 Tw T*
(this risk)Tj
0 Tc 0 Tw 6.5 0 0 6.5 86.1909 680.4615 Tm
(30)Tj
10 0 0 10 92.6909 677.1616 Tm
(.)Tj
-0.00011 Tc 0.108 Tw -2.6691 -1.2 Td
(In conclusion we note that although risk factor profiles)Tj
0.06889 Tw -1.2 -1.2 Td
(could influence the incidence of certain solid malignancies)Tj
0.287 Tw T*
(in SLE, modification of these factors \(particularly with)Tj
0.032 Tw T*
[(respect to reproductive issues\) may not be practical. )54.8 (All the)]TJ
0.12959 Tw T*
(same, we should recognize and attempt where possible to)Tj
0.0289 Tw T*
(minimize the impact of cancer risk factors such as smoking)Tj
0.02499 Tw T*
[(and obesity)64.8 (.)]TJ
/T1_1 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_0 1 Tf
-0.002 Tw 8 0 0 8 54 559.1616 Tm
[(W)79.9 (e are grateful to Dr)54.8 (. R. Ramsey-Goldman for providing the questionnaire)]TJ
0.1667 Tw 0 -1.25 TD
[(for determination of risk factors for malignancies. )17.7 (W)79.9 (e acknowledge the)]TJ
0.02499 Tw T*
[(technical assistance of )17.7 (T)35 (ina Panaritis.)]TJ
/T1_1 1 Tf
0 Tw 10 0 0 10 54 515.1616 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 505.1616 Tm
[(1.)-500.1 (Sweeney DM, Manzi S, Janosky J, et al. Risk of malignancy in)]TJ
1.25 -1.25 Td
(women with SLE. J Rheumatol 1995;22:1478-2.)Tj
-1.25 -1.25 Td
[(2.)-500.1 (Ramsey-Goldman R, Clarke )54.8 (A. Double trouble: are lupus and )]TJ
1.25 -1.25 Td
(malignancy associated? Lupus 2001;10:388-91.)Tj
-1.25 -1.25 Td
[(3.)-500.1 (Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the)]TJ
0 Tc 1.25 -1.25 Td
[(risk of malignancy)64.9 (. Lupus 2001;10:394-400.)]TJ
-0.00011 Tc -1.25 -1.25 Td
[(4.)-500.1 (Pettersson )17.7 (T)74 (, Pukkala E, )17.7 (T)69.9 (eppo L, Friman C. Increased risk of)]TJ
1.25 -1.25 Td
[(cancer in patients with systemic lupus erythematosus. )54.8 (Ann Rheum)]TJ
T*
(Dis 1992;51:437-9.)Tj
-1.25 -1.25 Td
[(5.)-500.1 (Ramsey-Goldman R, Mattai SA, Schilling E, et al. Increased risk of)]TJ
1.25 -1.25 Td
(malignancy in patients with systemic lupus erythematosus. J Invest)Tj
0 Tc T*
(Med 1998;46:217-22.)Tj
-0.00011 Tc -1.25 -1.25 Td
[(6.)-500.1 (Sultan SM, Ioannou )36.8 (Y)128.9 (, Isenber)17.7 (g DA. Is there an association of)]TJ
1.25 -1.25 Td
[(malignancy with SLE? )54.8 (An analysis of 276 patients under long-term)]TJ
T*
[(review)64.8 (. Rheumatology 2000;39:1)36.8 (147-52.)]TJ
-1.25 -1.25 Td
[(7.)-500.1 (Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic)]TJ
1.25 -1.25 Td
[(lupus erythematosus. )54.8 (Arthritis Rheum 1996;39:1050-4.)]TJ
-1.25 -1.25 Td
[(8.)-500.1 (Nived O, Bengtsson )54.8 (A, Jonsen )54.8 (A, Sturfelt G, Olsson H.)]TJ
1.25 -1.25 Td
(Malignancies during follow-up in an epidemiologically defined SLE)Tj
T*
(inception cohort in southern Sweden. Lupus 2001;10:500-4.)Tj
-1.25 -1.25 Td
[(9.)-500.1 (Bernatsky S, Boivin J, Clarke )54.8 (A, Rajan R. Cancer risk in SLE: )54.8 (A)]TJ
1.25 -1.25 Td
[(meta-analysis [abstract]. )54.8 (Arthritis Rheum 2001;44 Suppl:S244.)]TJ
-1.75 -1.25 Td
[(10.)-500.1 (T)69.9 (alal N. )54.8 (Autoimmunity and lymphoid malignancy in New Zealand)]TJ
1.75 -1.25 Td
(black mouse. Prog Clin Immunol 1974;2:101-20.)Tj
-1.7131 -1.25 Td
[(1)36.8 (1)-0.1 (.)-500.1 (Hamblin )17.7 (TJ, Oscier DG, )36.8 (Y)99.8 (oung BJ. )54.8 (Autoimmunity in chronic)]TJ
1.7131 -1.25 Td
(lymphocytic leukaemia. J Clin Pathol 1986;39:713-6.)Tj
-1.75 -1.25 Td
[(12.)-500.1 (Conley CL, Misiti J, Laster )54.8 (AJ. Genetic factors predisposing to)]TJ
1.75 -1.25 Td
(chronic lymphocytic leukemia and to autoimmune disease. Medicine)Tj
0 Tc 0 Tw T*
(1980;59:323-34.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(13.)-500.1 (Caligaris-Cappio F)79.7 (. B-chronic lymphocytic leukemia: )54.8 (A)-220.1 (malignancy)]TJ
1.75 -1.25 Td
(of anti-self B cells. Blood 1996;87:2615-20.)Tj
31.25 63.671 Td
[(14.)-500.1 (Kipps )17.7 (TJ, Carson CA. )54.8 (Autoantibodies in chronic lymphocytic)]TJ
1.75 -1.25 Td
(leukemia and related systemic autoimmune diseases. Blood)Tj
0 Tc 0 Tw T*
(1993;81:2475-87.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(15.)-500.1 (Sthoeger ZM, )17.7 (W)79.9 (akai M, )17.7 (T)69.9 (se DB, et al. Production of autoantibodies)]TJ
1.75 -1.25 Td
(by CD5-expressing B lymphocytes from patients with chronic)Tj
T*
(lymphocytic leukemia. J Exp Med 1989;169:255-68.)Tj
-1.75 -1.25 Td
[(16.)-500.1 (T)69.9 (an EM, Cohen )54.8 (AS, Fries JF)79.7 (, et al. )17.7 (The 1982 )54.8 (American College of)]TJ
1.75 -1.25 Td
[(Rheumatology revised criteria for the classification of SLE. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1982;25:1271-7.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(17.)-500.1 (Hochber)17.7 (g MC. Updating the )54.8 (American College of Rheumatology)]TJ
1.75 -1.25 Td
(revised criteria for the classification of systemic lupus erythematosus)Tj
T*
[([letter]. )54.8 (Arthritis Rheum 1997;40:1725.)]TJ
-1.75 -1.25 Td
[(18.)-500.1 (National Population Health Survey)64.8 (, 1996-97 [computer file]: public)]TJ
1.75 -1.25 Td
(use microdata files: household component. [[82M0009XCB]]. 1998.)Tj
T*
(Ottawa, Statistics Canada, Health Statistics Division. )Tj
-1.75 -1.25 Td
[(19.)-500.1 (Guess HA, )17.7 (W)79.9 (est R, Strand LM, et al. Fatal upper gastrointestinal)]TJ
1.75 -1.25 Td
(hemorrhage or perforation among users and nonusers of nonsteroidal)Tj
T*
(anti-inflammatory drugs in Saskatchewan, Canada 1983. Clin)Tj
T*
(Epidemiol 1988;41:35-45.)Tj
-1.75 -1.25 Td
[(20.)-500.1 (Byers )17.7 (T)74 (, Nestle M, McT)34.8 (iernan )54.8 (A, et al. )54.8 (American Cancer Society)]TJ
1.75 -1.25 Td
(guidelines on nutrition and physical activity for cancer prevention:)Tj
T*
(Reducing the risk of cancer with healthy food choices and physical)Tj
T*
[(activity)64.8 (. CA)-220.2 (Cancer J Clin 2002;52:92-1)36.8 (19.)]TJ
-1.75 -1.25 Td
[(21.)-500.1 (Bernatsky S. Malignancy in systemic lupus erythematosus )]TJ
1.75 -1.25 Td
([dissertation]. Montreal: McGill University; 2001.)Tj
-1.75 -1.25 Td
[(22.)-500.1 (Dhar J, Kmak D, Bhan R, Pishorodi L, )54.8 (Ager J, Sokol R. )54.8 (Abnormal)]TJ
1.75 -1.25 Td
(cervicovaginal cytology in women with lupus: a retrospective cohort)Tj
T*
[(study)64.9 (. Gynecol Oncol 2001;82:4-6.)]TJ
-1.75 -1.25 Td
[(23.)-500.1 (Bateman H, )36.8 (Y)99.8 (azici )36.8 (Y)128.9 (, Lef)17.7 (f L, Peterson M, Paget SA. Increased)]TJ
1.75 -1.25 Td
(cervical dysplasia in intravenous cyclophosphamide-treated patients)Tj
T*
[(with SLE: a preliminary study)64.8 (. Lupus 2000;9:542-4.)]TJ
-1.75 -1.25 Td
[(24.)-500.1 (Y)99.8 (ell JA, Bur)17.7 (ge SM. )17.7 (W)79.9 (arts and lupus erythematosus. Lupus)]TJ
0 Tw 1.75 -1.25 Td
(1993;2:21-3.)Tj
0.02499 Tw -1.75 -1.25 Td
[(25.)-500.1 (W)79.9 (ard MM, Studenski S. Clinical prognostic factors in lupus)]TJ
1.75 -1.25 Td
[(nephritis. )17.7 (The importance of hypertension and smoking. )54.8 (Arch Intern)]TJ
0 Tc T*
(Med 1992;152:2082-8.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(26.)-500.1 (Petri M, Perez-Gutthann S, Spence D, Hochber)17.7 (g MC. Risk factors)]TJ
1.75 -1.25 Td
[(for coronary artery disease in patients with SLE. )54.8 (Am J Med)]TJ
0 Tc 0 Tw T*
(1992;93:513-9.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(27.)-500.1 (Rahman P)110.7 (, Urowitz MB, Gladman DD, Bruce IN. Contribution of)]TJ
1.75 -1.25 Td
(traditional risk factors to coronary artery disease in patients with)Tj
T*
(SLE. J Rheumatol 1999;26:2363-8.)Tj
-1.75 -1.25 Td
[(28.)-500.1 (McAlindon )17.7 (T)74 (, Giannotta L, )17.7 (T)69.9 (aub N, D\325Cruz D, Hughes G.)]TJ
1.75 -1.25 Td
(Environmental factors predicting nephritis in systemic lupus )Tj
0 Tc T*
[(erythematosus. )54.9 (Ann Rheum Dis 1993;52:720-4.)]TJ
-0.00011 Tc -1.75 -1.25 Td
[(29.)-500.1 (Bruce IN, Gladman DD, Urowitz MB. Detection and modification)]TJ
1.75 -1.25 Td
(of risk factors for coronary artery disease in patients with systemic)Tj
T*
[(lupus erythematosus: a quality improvement study)64.8 (. Clin Exp)]TJ
T*
(Rheumatol 1998;16:435-40.)Tj
-1.75 -1.25 Td
[(30.)-500.1 (Bernatsky S, Clarke )54.8 (A, Ramsey-Goldman R. Malignancy and)]TJ
1.75 -1.25 Td
(systemic lupus erythematosus. Curr Rheumatol Rep 2002;4:351-8.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
8 0 0 8 420.3613 35.9844 Tm
(The Journal of Rheumatology 2002; 29:12)Tj
0 Tc 0 Tw -45.7952 -0.0313 Td
(2554)Tj
ET
0 0 0 0 k
/GS0 gs
105.25 58.75 407.5 -10.83 re
f*
0.5 w
105.25 58.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
21 0 obj
<>stream
8;Z\6!H%uo#ikq,j?(g>_3fo2-#'R2Up+`PeJ,5B:/t)[pfAWJ;%?i\b/sMFH<`\8
\OrTb8P9,a-+7%X%`X+"4KLidgZ@/RFt]qcoqV4F4kX85X5%%oiQ6Gq?#Z>*8rbhAY10%DTUMC@7OnTll;t3u4RY'bH
q*Yi',u+>hQhhjtFDU%KaI,`Ua8gfhI
.'X^W`jj*+QJ:Vm.V_4A$nC^B)OZ^F[=;9<@(##eVYS
$I.(85\s;501ODU%oK^L.#jI*Qh;lqUX#<[+SeTkjA=8pOe0;
%a:ejb>EX\*4oF;WHr)6G-0Bt^[?*1(PDM,]CibgJO^>Z$+Bq=c12?e"l9<85+*#a
R>%o>hJn,6U?bT#8o]D5]AIXPWUG*BpVMo.FK5`E]Q[B(W7-%`,'E!7kbUcnq.qi+bK@,C^3>JEU35-4o&0osXG"rjifF4IB
Bd>'$S2bNJQQ[;&9X7n%XhGQho'd[^>Zn]/2ZP:KEX2~>
endstream
endobj
25 0 obj
[/Indexed/DeviceRGB 255 24 0 R]
endobj
24 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
48 0 obj
<>
endobj
56 0 obj
<>
endobj
45 0 obj
<>
endobj
83 0 obj
<>
endobj
114 0 obj
<>
endobj
44 0 obj
<>
endobj
76 0 obj
<>stream
HUiPSY~/0%imJEDulTDlQA-%Y",Ҹ!:Ҷ[{43jkuPӎ}^5LMϏSխs~w/00]CÂGRҥ
4\Aгm<&c{o֡ԟ5?H6_eeўc/N욶Ao^rhLhW\jA@8^(!ʄRAp^$], ^@"
%YDRA@&KI}QX&O
qi '͌DqPk{!íd`,̝}[B$+iZAK r%Yta`Y/)smEؽ3+g2f~2fR:;)NiN_8w2"ҹvZf'>mtsr(XC6___"'jzdln8YiL,U͊#24;5WӰKJ#q2A#(L(9l4řbNaŽoy2JY)Z\3мve]5\ix#fopL? ݛM]z5KQV=6Sk/